Can immunotherapy boost surgery outcomes in recurrent head and neck cancer?
NCT ID NCT07751289
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This trial is testing whether adding an immunotherapy drug (PD-1 antibody) to standard treatment can improve outcomes for people with recurrent head and neck cancer. Participants will be randomly assigned to receive either the immunotherapy before and after surgery, or standard surgery and post-operative treatment. The study aims to see if the immunotherapy approach extends the time before the cancer returns or spreads, and to check its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PD-1 antibody (an immunotherapy drug) given with chemotherapy before surgery and alone after surgery
- What this could lead to
- If successful, this approach could improve event-free survival for people with recurrent head and neck cancer, potentially offering a better chance at controlling the disease.
- What could go wrong
- This is a phase 2 trial, so results are preliminary. The treatment may not improve outcomes and could cause side effects like immune-related inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?
- Sharper radiation boost aims to tackle head and neck cancers that return
- New combo attack: immunotherapy plus chemo before surgery for head and neck cancer
- New drug cocktail shows promise for tough head and neck cancers
- Remote hearing tests could save cancer Patients' hearing
- New drug cocktail aims to extend life in Tough-to-Treat head and neck cancer